Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Cathleen Spath"'
Autor:
Rouven Hoefflin, Bernd Lahrmann, Gregor Warsow, Daniel Hübschmann, Cathleen Spath, Britta Walter, Xin Chen, Luisa Hofer, Stephan Macher-Goeppinger, Yanis Tolstov, Nina Korzeniewski, Anette Duensing, Carsten Grüllich, Dirk Jäger, Sven Perner, Gita Schönberg, Joanne Nyarangi-Dix, Sanjay Isaac, Gencay Hatiboglu, Dogu Teber, Boris Hadaschik, Sascha Pahernik, Wilfried Roth, Roland Eils, Matthias Schlesner, Holger Sültmann, Markus Hohenfellner, Niels Grabe, Stefan Duensing
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-12 (2016)
It has been increasingly recognised that tumours are not made up of a homogeneous population of cells. Here, the authors show heterogeneous expression of five protein markers in renal cell cancer and demonstrate that the progression of the tumour doe
Externí odkaz:
https://doaj.org/article/6b8b3ea588cd4746baa64e76cce15f72
Autor:
Stefan Fuxius, Cathleen Spath, Sascha Pahernik, Sonia Vallet, Dirk Jäger, Carsten Grüllich, Stefanie Zschäbitz, Markus Hohenfellner, Stefan Duensing, Boris Hadaschik, Daniel Debatin, Andreas Karcher
Publikováno v:
Journal of Cancer
Purpose: Several new treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) have been approved within the last years - among them cabazitaxel (CAB), abiraterone acetate, enzalutamide, and radium-223. The aim of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82cfd42751a06079a8285a23a0bfe5b5
https://doi.org/10.7150/jca.17644
https://doi.org/10.7150/jca.17644
Autor:
Sergey Leontyev, Rudolf Rübsamen, Stefan Dhein, Franziska Schlegel, Martin Kostelka, Martin Nichtitz, Aida Salameh, Andreas Boldt, Ronny Schmiedel, Cathleen Spath, Friedrich-Wilhelm Mohr
Publikováno v:
European Journal of Heart Failure. 15:23-35
Aim The aim of this study was to characterize an alternative treatment for dilated cardiomyopathy (DCM) using a novel cardiac biological assist device created from engineered heart tissue (EHT). Methods and results The EHTs were constructed in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3abee207cc635e7ab9c5648060f025ce
https://doi.org/10.1093/eurjhf/hfs200
https://doi.org/10.1093/eurjhf/hfs200
Autor:
Carsten Grüllich, Wilfried Roth, Niels Grabe, Yanis Tolstov, Gita Schönberg, Luisa Hofer, Matthias Schlesner, Gregor Warsow, Gencay Hatiboglu, Joanne Nyarangi-Dix, Markus Hohenfellner, Dogu Teber, Boris Hadaschik, Britta Walter, Anette Duensing, Sanjay Isaac, Nina Korzeniewski, Sascha Pahernik, Dirk Jäger, Rouven Hoefflin, Xin Chen, Roland Eils, Stephan Macher-Goeppinger, Bernd Lahrmann, Holger Sültmann, Sven Perner, Daniel Hübschmann, Stefan Duensing, Cathleen Spath
Publikováno v:
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-12 (2016)
Nature Communications, Vol 7, Iss 1, Pp 1-12 (2016)
Intratumoural heterogeneity (ITH) is a major cause of cancer-associated lethality. Extensive genomic ITH has previously been reported in clear cell renal cell carcinoma (ccRCC). Here we address the question whether ITH increases with malignant progre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aac812da8083972f863cc8e5ba4be59e
https://doi.org/10.1038/ncomms11845
https://doi.org/10.1038/ncomms11845
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 4 (2013)
Frontiers in Pharmacology, Vol 4 (2013)
Background: Recently, we demonstrated the beneficial effects of engineered heart tissues for the treatment of dilated cardiomyopathy in rats. For further development of this technique we started to produce engineered tissue (ET) from mesenchymal stem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2de80d60ac16434741a0c3ec23dc43a
https://ul.qucosa.de/id/qucosa:80247
https://ul.qucosa.de/id/qucosa:80247
Autor:
Sascha Pahernik, Stefan Duensing, Cathleen Spath, Sonia Vallet, Dirk Jäger, Carsten Grüllich, Markus Hohenfellner, Stefanie Zschaebitz, Boris Hadaschik
Publikováno v:
Journal of Clinical Oncology. 34:e16511-e16511
e16511Background: Several newtreatment options for patients with mCRPC have been approved within the last years - among them cabazitaxel, abiraterone acetate, enzalutamide, and radium-223. No facto...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5d9c62167e96a9a0ed391f652080978
https://doi.org/10.1200/jco.2016.34.15_suppl.e16511
https://doi.org/10.1200/jco.2016.34.15_suppl.e16511